Clinical applications of zolmitriptan (Zomig(TM), 311C90)

Richard B. Lipton, W. F. Stewart

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Zolmitriptan (Zomig(TM), formerly 311C90) is a novel, oral antimigraine drug that is consistently effective and well tolerated in the acute treatment of migraine headache and its associated symptoms. The purpose of this article is to review data available from pharmacological and clinical trials with zolmitriptan and to summarize the clinically relevant features that distinguish this agent. We will review the attributes desirable in a migraine drug and use this as a template for assessing zolmitriptan. Zolmitriptan provides a new oral treatment option for physicians which should help improve patient outcomes.

Original languageEnglish (US)
Pages (from-to)53-59
Number of pages7
JournalCephalalgia, Supplement
Volume17
Issue number18
StatePublished - 1997

Fingerprint

zolmitriptan
Migraine Disorders
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Clinical applications of zolmitriptan (Zomig(TM), 311C90). / Lipton, Richard B.; Stewart, W. F.

In: Cephalalgia, Supplement, Vol. 17, No. 18, 1997, p. 53-59.

Research output: Contribution to journalArticle

@article{dbd6b00396cf46389e605931b1ef079c,
title = "Clinical applications of zolmitriptan (Zomig(TM), 311C90)",
abstract = "Zolmitriptan (Zomig(TM), formerly 311C90) is a novel, oral antimigraine drug that is consistently effective and well tolerated in the acute treatment of migraine headache and its associated symptoms. The purpose of this article is to review data available from pharmacological and clinical trials with zolmitriptan and to summarize the clinically relevant features that distinguish this agent. We will review the attributes desirable in a migraine drug and use this as a template for assessing zolmitriptan. Zolmitriptan provides a new oral treatment option for physicians which should help improve patient outcomes.",
author = "Lipton, {Richard B.} and Stewart, {W. F.}",
year = "1997",
language = "English (US)",
volume = "17",
pages = "53--59",
journal = "Cephalalgia, Supplement",
issn = "0800-1952",
publisher = "Wiley-Blackwell",
number = "18",

}

TY - JOUR

T1 - Clinical applications of zolmitriptan (Zomig(TM), 311C90)

AU - Lipton, Richard B.

AU - Stewart, W. F.

PY - 1997

Y1 - 1997

N2 - Zolmitriptan (Zomig(TM), formerly 311C90) is a novel, oral antimigraine drug that is consistently effective and well tolerated in the acute treatment of migraine headache and its associated symptoms. The purpose of this article is to review data available from pharmacological and clinical trials with zolmitriptan and to summarize the clinically relevant features that distinguish this agent. We will review the attributes desirable in a migraine drug and use this as a template for assessing zolmitriptan. Zolmitriptan provides a new oral treatment option for physicians which should help improve patient outcomes.

AB - Zolmitriptan (Zomig(TM), formerly 311C90) is a novel, oral antimigraine drug that is consistently effective and well tolerated in the acute treatment of migraine headache and its associated symptoms. The purpose of this article is to review data available from pharmacological and clinical trials with zolmitriptan and to summarize the clinically relevant features that distinguish this agent. We will review the attributes desirable in a migraine drug and use this as a template for assessing zolmitriptan. Zolmitriptan provides a new oral treatment option for physicians which should help improve patient outcomes.

UR - http://www.scopus.com/inward/record.url?scp=0030781088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030781088&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 53

EP - 59

JO - Cephalalgia, Supplement

JF - Cephalalgia, Supplement

SN - 0800-1952

IS - 18

ER -